High costs of GLP-1 receptor agonists like Wegovy and Zepbound—often exceeding $1,000 monthly—limit access for patients seeking effective obesity and diabetes treatments. These barriers fuel demand for innovativ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.